3 news items
Legend Biotech Reports First Quarter 2024 Results and Recent Highlights
LEGN
13 May 24
of 2025. The expansion of our partnership with Novartis demonstrates our commitment to ensuring every patient who needs CARVYKTI can access
On Friday April 5, 2024, Legend Biotech Reported CARVYKTI Becomes The First And Only BCMA-Targeted CAR-T Cell Therapy Approved By The FDA For Second-Line Treatment Of Multiple Myeloma
LEGN
8 Apr 24
needed," said Ying Huang, Ph.D., Chief Executive Officer of Legend Biotech. "We are committed to improving the lives of patients battling blood cancer
Legend Biotech's CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma
LEGN
5 Apr 24
are desperately needed," said Ying Huang, Ph.D., Chief Executive Officer of Legend Biotech. "We are committed to improving the lives of patients battling
- Prev
- 1
- Next